Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.ONS · Entity 608 | Director | November 28, 2016 | November 30, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date November 28, 2016 · Filed November 30, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,939 |
Reported balance
After 2016-11-28 transaction · row 1
1 source rowRow 1 · 2016-11-28 · Other · Acquired 1,939 · Balance 1,939 F1: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2019-11-08 | Direct | 1,260 |
Reported balance
After 2016-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-11-28 · Other · Acquired 1,260 · Balance 1,260 F1: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F2: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member.
F2: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2016 Filed Nov 30, 2016 22:27 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherWarrant (Right to Buy) · Derivative | 1,260 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001209191-16-152515 · doc4.xml · derivative · entry 2 Smith Hoke Robin · CIK 0001665314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Underlying: Common Stock · 1,260 shares Expires 2019-11-08 F1 · kind: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · price: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F2 · derivative.exercise_date: Immediately exercisable. F1 · derivative.underlying_shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · balance_after: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. Read SEC document |
| November 28, 2016 Filed Nov 30, 2016 22:27 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | OtherCommon Stock | 1,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152515 · doc4.xml · nonDerivative · entry 1 Smith Hoke Robin · CIK 0001665314 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939 F1 · kind: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · price: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.